Clinical Trials Browser

Phase 3 × Fallopian Tube Neoplasms × 30 days × Clear all

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

186 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

770 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04575935 2026-03-05

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Phase 3 Recruiting

580 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-02-27

OVATION-3

Phase 3 Recruiting

500 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

520 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms